DEF 14A: PDS Biotech Seeks Stockholder Approval for Increased Share Authorization and Director Elections at Upcoming Annual Meeting

PDS Biotechnology Corporation is holding its Annual Meeting of Stockholders on June 24, 2024, to elect directors, approve an increase in authorized common stock, ratify the selection of KPMG LLP as its auditor, and conduct an advisory vote on executive compensation.

Summary

• PDS Biotechnology Corporation will hold its Annual Meeting of Stockholders virtually on June 24, 2024, at 9 a.m. Eastern Time.
• Stockholders of record as of April 26, 2024, are eligible to vote.
• The meeting will address the election of two Class C directors (Frank Bedu-Addo and Otis Brawley), an amendment to increase authorized common stock from 75,000,000 to 150,000,000 shares, ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The Board of Directors recommends voting in favor of all proposals.
• The company had 36,679,275 shares of common stock outstanding as of the record date.
• The company engaged Morrow Sodali to assist in the solicitation of proxies for a fee not expected to exceed $40,000.
• The Third Restated Plan increased the number of shares of Common Stock authorized for issuance from 4,165,535 to 6,565,535.
• As of December 31, 2023, there were 3,051,449 shares available for grant under the Third Restated Plan.
• On January 22, 2024, the Inducement Plan was further amended to increase the total number of shares of Common Stock reserved for issuance thereunder from 1,100,000 shares to 2,100,000 shares.
• As of December 31, 2023, there were 112,010 shares available for grant under the Inducement Plan.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the proposals for the upcoming annual meeting. The Board's recommendations to vote in favor of all proposals suggest a positive outlook, but the potential for dilution with the increased share authorization tempers the overall sentiment.

Positives

• The Board recommends voting in favor of all proposals, indicating confidence in the company's direction.
• The proposed increase in authorized shares provides flexibility for future business needs, including potential capital raises, acquisitions, and equity incentives.
• The company is committed to corporate responsibility, including environmental, social, and governance (ESG) issues.

Negatives

• Increasing the number of authorized shares could dilute existing stockholders' ownership percentage and voting power.
• The company incurred a net loss of $42,942,000 in 2023.

Risks

• Failure to approve the increase in authorized shares may constrain the company's ability to raise capital and execute its business strategy.
• The biopharmaceutical industry is characterized by a very long product development cycle, including a lengthy R&D period and a rigorous regulatory approval process.

Future Outlook

The company believes that increasing the number of authorized shares will provide flexibility for future business needs, including raising capital, providing equity incentives, and pursuing strategic relationships and acquisitions.

Management Comments

• The Board has unanimously determined that the Authorized Shares Amendment is advisable and in the best interests of the company and our stockholders and recommends that our stockholders approve the Authorized Shares Amendment.

Industry Context

As a clinical-stage biotech company, PDS Biotech's executive compensation program does not primarily rely on financial results but focuses on advancing its pipeline and bringing product candidates to market.

Comparison to Industry Standards

• The form of employment agreement was reviewed by our Board of Directors and by the Compensation Committees independent compensation consultant to determine whether its provisions are consistent with the employment agreements of our benchmarking peer group.
• Although we believe that each company in our benchmarking peer group understandably has forms of employment agreements that are different from ours, we believe key employment contract provisions covering our executive officers are in line with market practice and provide terms designed to attract and retain executive officers.

Management Changes

Corporate Governance

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution or increased company value.
• Executive compensation decisions affect the alignment of management's interests with those of the shareholders.
• The selection of an independent auditor ensures the integrity of financial reporting.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 24, 2024.
• If approved, the company will file the Authorized Shares Amendment with the Secretary of State of Delaware.
• The Board will consider the results of the advisory vote on executive compensation when evaluating the executive compensation program.

Key Dates

Keywords

proxy statement, annual meeting, directors, authorized shares, KPMG, executive compensation, stockholders, PDS Biotech